| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1d3b6e03a92d64f0e4893a8b297f7647 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-36143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-711 |
| filingDate |
1998-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2002-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f48b7d88175b21d87d64b1c9946438a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b54e8f9310472117302321ea2bc648eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2023fe793f05127fc2a2322768982170 |
| publicationDate |
2002-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6475780-B1 |
| titleOfInvention |
Alphavirus vectors for paramyxovirus vaccines |
| abstract |
A DNA vector comprises a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, and a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory syncytial virus fusion (RSV F) protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, the first and second DNA sequences being under the transcriptional control of a promoter, preferably a cytomegalovirus promoter, which may include Intron A. Such vectors also contain a further nucleotide sequence located between the promoter sequence and the alphavirus sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such DNA vectors may be used to immunize a host against disease caused by infection with RSV or other paramyxovirus, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purposes. Such vectors also may be used to produce antibodies for detection of RSV or other paramyxovirus infection in a sample. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2811027-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7541038-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007128222-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2848692-A1 |
| priorityDate |
1997-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |